- Case report
- Open Access
- Open Peer Review
Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report
© Lahbabi et al.; licensee BioMed Central Ltd. 2012
- Received: 30 March 2012
- Accepted: 26 June 2012
- Published: 4 September 2012
The combination of polyethylene glycol (PEG)ylated interferon (pegylated interferon) and ribavirin has been shown to be an effective treatment for chronic hepatitis C virus. In general, common side effects related to this combination therapy are mild and are well tolerated. However, peripheral neuropathy including demyelinating polyneuropathy related to PEG-interferon α2a (pegylated interferon alfa-2a) is extremely rare. In the literature, only one case of acute inflammatory demyelinating polyneuropathy related to PEG-interferon α2a has been published previously.
To the best of our knowledge we present only the second case of acute inflammatory demyelinating polyneuropathy related to PEG-interferon α2a, occurring in a 63-year-old Caucasian man. He developed tingling, numbness, and weakness of his upper and lower extremities with acute neurological deficits after five weeks of a combination therapy with PEG-interferon α2a and ribavirin for chronic hepatitis C virus infection. His clinical course, neurological findings, and his electromyogram results were all consistent with acute inflammatory demyelinating polyneuropathy. Our patient recovered completely after interferon was stopped and symptomatic treatment and a further electromyogram showed a disappearance of neuropathy. Four weeks later, PEG-interferon α2a was reintroduced with a gradually increasing dose without any reappearance of neurological symptoms allowing hepatitis C seroconversion.
Recognition of this rare yet possible presentation is important for early and accurate diagnosis and treatment. This case report also suggests that the reintroduction of PEGylated interferon in patients who had presented with acute inflammatory demyelinating polyneuropathy related to interferon α may be safe, but this must be confirmed by further studies.
- Inflammatory demyelinating polyneuropathy
- PEGylated interferon
- Viral hepatitis C infection
Interferon α (IFNα) has been widely used for the treatment of chronic viral hepatitis. Overall, the common side effects associated with this drug are well known. The common side effects of IFN include flu-like symptoms, and psychiatric symptoms such as depression, suicidal ideation, irritability, nervousness, and insomnia . Less common side effects include hematopoietic suppression, reversible hair loss, hearing loss, retinopathy, dermatitis, seizures, and the development or exacerbation of autoimmune diseases such as thyroid dysfunction, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, vitiligo, type 1 diabetes, and myasthenia gravis . Peripheral neuropathy is a rare and uncommon side effect seen in patients treated with IFNα . In recent years, a variety of peripheral neuropathies have been reported in patients treated with IFN including sensory neuropathy, autonomic neuropathy, Bell’s palsy, and more recently, chronic inflammatory demyelinating polyneuropathy (CIDP) . To date, only one case of acute inflammatory demyelinating polyneuropathy (AIDP) related to polyethylene glycol (PEG)ylated interferon alfa-2a (PEG-IFNα2a) has been published. To the best of our knowledge, this is only the second case of severe AIDP related to PEG-IFNα2a, which developed at week five of IFNα2a therapy initiated for hepatitis C virus infection and where the gradual reintroduction of IFN was safe and without any residual neuromuscular deficits.
A 63-year-old Caucasian man presented to our hospital for chronic hepatitis C treatment. His initial physical examination results were unremarkable. An initial liver profile included aspartate aminotransferase (AST) 60IU/mL, alanine aminotransferase (ALT) 74IU/mL, total bilirubin 1mg/dL, alkaline phosphatase 81IU/mL, albumin 5.2g/dL, and a prothrombin time (PT) of 76%. Serum viral load was estimated to 3,545,770IU/mL (6.5log) with a genotype 2a2c. The assessment of liver fibrosis by FibroTest® and FibroScan® revealed a stage F2 of fibrosis. An abdominal ultrasound did not find any signs of portal hypertension or cirrhosis. Upper gastrointestinal endoscopy did not find any endoscopic signs of portal hypertension. He was started on a course of treatment comprising PEG-interferon α2a (PEGASYS®) 180μg subcutaneously per week and ribavirin 800mg/day in divided doses orally. A rapid virological response was obtained after four weeks.
Electromyogram/nerve conduction studies
Distal latency (m/s)
Conduction velocity (m/s)
Amplitude (uV (sensory) mV (motor))
Minimum F-wave latency (ms)
The more probable etiologies of demyelinating polyneuropathy in our patient included infectious processes, toxins and/or drugs, and immune mediated processes . Viral infections such as hepatitis C virus (HCV), HIV and CMV have been described to cause demyelinating neuropathy . Since polyneuropathy developed after the negative conversion of HCV-ribonucleic acid (RNA) transcript, and both HIV test and CMV DNA results were negative in our patient, these were not the cause of his neuropathy. Toxins and/or drugs are also common etiologies for demyelinating neuropathies, which can be acute or chronic in nature . Common toxins/drugs are barbital, sulfonamides, phenytoin, nitrofurantoin, heavy metals, carbon monoxide, industrial poisons, and certain drugs used for acquired immunodeficiency syndrome (AIDS) (zalcitabine, didanosine) . Our patient had no exposure to any of these toxins or drugs other than PEGASYS® and ribavirin. Indeed, ribavirin has not been associated with any type of reported neuropathy, but PEGASYS® including IFNα has been implicated to cause immune-mediated CIDP during chronic hepatitis C treatment due to cytokine-induced apoptosis in the myelin-producing oligodendrocytes, resulting in inhibition of central nervous system remyelination . The timecourse for our patient’s symptoms was not long enough to meet the criteria for a CIDP. The criteria for CIDP usually include the clinical deterioration of neurological symptoms for a period greater than eight weeks, as opposed to AIDP, which usually has deterioration over a period of approximately four weeks or less as in our patient’s case . The pathogenesis of AIDP related to PEGASYS® use is thought to be an acute immune-mediated progress. The precise and exact immune regulatory function of IFNα including PEG-IFN is not well understood, and it is likely similar to the mechanism associated with IFN-induced CIDP described above [3, 8]. In addition, IFNα has been reported to enhance in vivo and in vitro autoantibody production and may upregulate transcription of genes associated with class I major histocompatibility complex (MHC) antigens . It is likely that the levels of pro-inflammatory cytokines may trigger autoimmune phenomena in immunologically predisposed individuals when IFN is administered. Therefore, the immune system mistakenly attacks the host’s nerve tissue after recognizing a molecular epitope similar to a foreign antigen and this may result in acute inflammatory neuropathy . In addition, there have been multiple reported cases of demyelinating neuropathy associated with cyroglobulinemia related to HCV . However, our patient had an undetectable cryoglobulin level on multiple occasions, which rules out a possibility of cryoglobulin-induced demyelinating neuropathy. Peripheral neuropathy related to PEGASYS® improves after stopping treatment; some cases may require the use of corticosteroids, plasmapheresis or immunosuppressive drugs . In our patient’s case his symptomatology improved significantly four weeks after stopping interferon and the use of a symptomatic treatment. Four weeks later, IFN was reintroduced with a gradually increasing dose without reappearance of his neurological symptoms.
Acute inflammatory demyelinating neuropathy is a rare complication of IFNα therapy. It is very important that gastroenterologists and hepatologists recognize this rare disorder for early diagnosis, management, and the prevention of long-term neurological deficits. This case report also suggests that the reintroduction of PEGylated interferon may be safe, but this must be confirmed by further studies.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Negro F: Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol. 2010, 24: 183-192. 10.1016/j.bpg.2009.10.012.View ArticlePubMedGoogle Scholar
- Tellez-Zenteno JF, Negrete-Pulido O, Nunez M, Estanol-Vidal B, Garcia-Ramos G: Peripheral neuropathy during a second cycle of treatment with high doses of interferon-alpha in a patient with hepatitis C, and a review of the literature. Rev Neurol. 2002, 35: 644-646.PubMedGoogle Scholar
- Meriggioli MN, Rowin J: Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve. 2000, 23: 433-435. 10.1002/(SICI)1097-4598(200003)23:3<433::AID-MUS17>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Stübgen JP: Interferon alpha and neuromuscular disorders. J Neuroimmunol. 2009, 207: 3-17. 10.1016/j.jneuroim.2008.12.008.View ArticlePubMedGoogle Scholar
- Wulff EA, Wang AK, Simpson DM: HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000, 59: 1251-1260. 10.2165/00003495-200059060-00005.View ArticlePubMedGoogle Scholar
- Marzo EM, Tintore M, Fabregues O, Montalban X, Codina A: Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-alpha. J Neurol Neurosurg Psychiatry. 1998, 65: 604-10.1136/jnnp.65.4.604.View ArticlePubMedPubMed CentralGoogle Scholar
- Van Doorn PA, Ruts L: Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol. 2004, 17: 607-613. 10.1097/00019052-200410000-00011.View ArticlePubMedGoogle Scholar
- Lin W, Kemper A, Dupree JL, Harding HP, Ron D, Popko B: Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain. 2006, 129: 1306-1318. 10.1093/brain/awl044.View ArticlePubMedGoogle Scholar
- Chung YH, Shong YK: Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am J Gastroenterol. 1993, 88: 244-247.PubMedGoogle Scholar
- Avila Funes JA, Mariona Montero VA, Melano Carranza E: Guillain Barre syndrome: etiology and pathogenesis. Rev Invest Clin. 2002, 54: 357-363.PubMedGoogle Scholar
- Vigani AG, Macedo-de-Oliveira A, Pavan MH, Pedro MN, Goncales FL: Hepatitis C virus infection, cryoglobulinemia, and peripheral neuropathy: a case report. Braz J Med Biol Res. 2005, 38: 1729-1734. 10.1590/S0100-879X2005001200001.View ArticlePubMedGoogle Scholar
- Cacoub P, Sène D, Saadoun D: Cryoglobulinemia. Rev Med Interne. 2008, 29: 200-208. 10.1016/j.revmed.2007.10.416.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.